These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 30392780)

  • 1. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
    Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
    Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep Learning Provides a New Magnetic Resonance Imaging-Based Prognostic Biomarker for Recurrence Prediction in High-Grade Serous Ovarian Cancer.
    Liu L; Wan H; Liu L; Wang J; Tang Y; Cui S; Li Y
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
    J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics.
    Ni M; Wan D; Wu J; Gong W; Wang J; Zheng Z
    J Proteomics; 2024 Jul; 304():105234. PubMed ID: 38925351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study.
    Yin R; Guo Y; Wang Y; Zhang Q; Dou Z; Wang Y; Qi L; Chen Y; Zhang C; Li H; Jian X; Ma W
    Acad Radiol; 2023 Sep; 30 Suppl 2():S192-S201. PubMed ID: 37336707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of MRI-Based Radiomics Model to Predict the Risk of Recurrence in Patients With Advanced High-Grade Serous Ovarian Carcinoma.
    Li HM; Gong J; Li RM; Xiao ZB; Qiang JW; Peng WJ; Gu YJ
    AJR Am J Roentgenol; 2021 Sep; 217(3):664-675. PubMed ID: 34259544
    [No Abstract]   [Full Text] [Related]  

  • 8. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative CT-based deep learning model for predicting overall survival in patients with high-grade serous ovarian cancer.
    Zheng Y; Wang F; Zhang W; Li Y; Yang B; Yang X; Dong T
    Front Oncol; 2022; 12():986089. PubMed ID: 36158664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
    Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
    Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning.
    Laios A; Katsenou A; Tan YS; Johnson R; Otify M; Kaufmann A; Munot S; Thangavelu A; Hutson R; Broadhead T; Theophilou G; Nugent D; De Jong D
    Cancer Control; 2021; 28():10732748211044678. PubMed ID: 34693730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
    Ahn B; Moon D; Kim HS; Lee C; Cho NH; Choi HK; Kim D; Lee JY; Nam EJ; Won D; An HJ; Kwon SY; Shin SJ; Jung HR; Kwon D; Park H; Kim M; Cha YJ; Park H; Lee Y; Noh S; Lee YM; Choi SE; Kim JM; Sung SH; Park E
    Nat Commun; 2024 May; 15(1):4253. PubMed ID: 38762636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer.
    Alves MR; Do Amaral NS; Marchi FA; Silva FIB; Da Costa AABA; Carvalho KC; Baiocchi G; Soares FA; De Brot L; Rocha RM
    Oncol Rep; 2019 Apr; 41(4):2254-2264. PubMed ID: 30720106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.